As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

Ankylosing spondylitis (AS) affects women differently than men. Ankylosing spondylitis symptoms in females may be less associated with the spine.

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Panelists discuss the challenges and evolving landscape of step therapy protocols in hidradenitis suppurativa treatment, emphasizing the impact on patient adherence, the potential benefits of earlier ...

The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions ...